AleraCare Holdings

What AleraCare Holdings does

AleraCare Holdings, founded in 2019 and headquartered in Phoenix, Arizona, is a U.S. healthcare provider specializing in ambulatory infusion therapy, specialty pharmacy, and home infusion services for patients with chronic and medically complex conditions — including multiple sclerosis, Crohn's disease, ulcerative colitis, lupus, rheumatoid arthritis, and other autoimmune and inflammatory disorders. Following its November 2025 merger with Pure Healthcare (a transaction backed by Hildred Capital Management and Build, respectively), the combined platform operates 77 infusion centers across 14 states under the Pure Infusion brand, administers 87 different biologic therapies, and offers private spa-like infusion suites with amenities such as 55-inch TVs, WiFi, and refreshments at a staff-to-patient ratio no greater than 1:3. The company holds Joint Commission Gold Seal of Approval accreditation and is positioned as a national outpatient alternative to hospital-based infusion delivery.

The platform's revenue model is recurring and insurance-mediated: services are billed primarily through in-network commercial payers, supplemented by co-pay assistance programs coordinated with drug manufacturers. Patient Access Coordinators handle insurance pre-authorization, and the company markets to both healthcare providers (via field-based Account Executives and Specialty Market Executives managing referrals) and directly to patients seeking a more comfortable infusion environment. The referral intake process is digital, including DocuSign-based order management, supporting a multi-channel intake model (digital, email, fax). The company was originally backed by St. Cloud Capital in 2019 and subsequently received a strategic investment from Hildred Capital Management in May 2023 to fund physical expansion and clinical capacity.

The combined entity's strategic posture is consolidation-oriented: the Pure Infusion brand consolidates Pure Healthcare, Pure Infusion Suites, and AleraCare into a single national platform, with stated goals of improving patient outcomes through integrated therapies and advanced technology, lowering healthcare costs, and capturing share in the ambulatory infusion segment. Operations are domestic-only across 14 states, and the leadership profile, ownership structure, and revenue figures are not publicly disclosed in the available source data.

Name

AleraCare Holdings

Legal name

AleraCare Holdings

Website

https://aleracare.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Short description

AleraCare Holdings is a U.S. healthcare provider operating a network of 77 ambulatory infusion centers across 14 states, delivering biologic infusion, specialty pharmacy, and home infusion services to patients with chronic autoimmune and complex conditions, now unified under the Pure Infusion brand.

Ownership category

akta.pro rank

Product category

Ambulatory Infusion Services

NAICS

All Other Outpatient Care Centers (621498), Other Ambulatory Health Care Services (6219), Ambulatory Health Care Services (621)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Health Services (8000)

akta.pro primary industry

Infusion Therapy Centers (Outpatient) (HLAFABAF)

akta.pro secondary industries

Infusion & Home Infusion Pharmacy Services (HLAFALAG), Home Infusion Therapy Providers (HLAFAEAE), Home Infusion Therapy & IV Nursing Services (HLADAFAG)

Keywords

• Infusion therapy services
• Specialty pharmacy services
• Home infusion therapy
• Ambulatory infusion care
• Biologic infusion treatments

Headquarters

HQ city

Phoenix

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Infusion Therapy Services: Revenue generated from providing outpatient biologic infusion and sub-cutaneous therapies for chronic conditions including MS, Crohn's, Colitis, Lupus, Rheumatoid Arthritis, and other autoimmune diseases
2. Specialty Pharmacy: Specialty pharmacy services providing medications for various therapeutic areas including immunology, neurology, gastroenterology, and oncology
3. Home Infusion Therapy: Home-based infusion services for Anti-Infectives, Entyvio, Immunoglobulin, Infliximab, Ocrevus, Orencia, Rituximab, TPN, and Vyvgart

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

AleraCare Holdings is a healthcare provider specializing in ambulatory infusion therapy, specialty pharmacy, and home infusion services for patients with chronic and medically complex conditions. Through its network of 77 infusion centers across 14 states, the company administers biologic and sub-cutaneous therapies for autoimmune diseases, neurological conditions, and other chronic disorders. Services are delivered under the Pure Infusion brand post-merger with Pure Healthcare and include comprehensive insurance pre-authorization, co-pay assistance, and provider referral coordination.

Product overview

AleraCare Holdings operates as a healthcare provider specializing in infusion and specialty pharmacy services. Following its merger with Pure Healthcare in November 2025, the combined company operates under the Pure Infusion brand as the new home for both Pure Healthcare and AleraCare. The portfolio consists of private infusion suites (Pure Infusion), specialty pharmacy services, home infusion therapy, and biologic treatments administered at outpatient locations. The company offers 87 different therapies across 75+ locations in 14 states.

Differentiator

Problem solved

Functional benefit

Products and services

• Outpatient Infusion Therapy (Pure Infusion) Ambulatory outpatient infusion therapy delivered in private spa-like infusion suites, administering 87 biologic and sub-cutaneous therapies for patients with chronic and medically complex conditions including autoimmune diseases and neurological disorders. Available across 77 infusion centers in 14 states with a 1:3 staff-to-patient ratio.
• Specialty Pharmacy Specialty pharmacy fulfillment and delivery services for patients with chronic and medically complex conditions, supporting the broader infusion therapy offering with insurance pre-authorization and co-pay assistance.
• Home Infusion Therapy Home and community-based infusion services for high-need and medically complex patients who cannot or prefer not to visit an outpatient infusion center, administered through AleraCare's network.

Quantifiable outcome

• 4.9 patient satisfaction rating
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Pure HealthcarecoreStrategic or Co-development Partner · 24 November 2025AleraCare and Pure Healthcare completed their merger in November 2025, creating a national platform for ambulatory infusion and specialty care with 77 infusion centers across 14 states
• Pure HealthcarecoreStrategic or Co-development Partner · 13 August 2025AleraCare and PURE Healthcare announced their intent to merge, forming a combined company with over 75 outpatient locations across 14 states to enhance infusion services and lower healthcare costs

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• InfuSystem Holdings: Provider of infusion services and medical equipment with exposure to biologic and chronic-condition therapies, operating an outpatient and home-based infusion model comparable to Pure Infusion.
• Soleo Health: Specialty home and alternate-site infusion provider focused on chronic and complex conditions, with specialty pharmacy integration — directly comparable to Pure Infusion's outpatient infusion, specialty pharmacy, and home infusion stack.
• KabaFusion: Specialty home infusion provider focused on IVIG, biologic, and chronic-condition therapies, with a national footprint overlapping Pure Infusion's therapy mix and referral-driven GTM.
• TwelveStone Health Partners: Specialty pharmacy and ambulatory infusion provider offering chronic biologic therapies and home infusion across multiple U.S. states, comparable in modality mix to Pure Infusion.
• Vivo Infusion: Ambulatory infusion center operator with private-suite patient experience models for chronic biologic therapies, directly mirroring Pure Infusion's outpatient center strategy.
• Amerita: Specialty home infusion provider delivering IVIG, anti-infectives, TPN, and chronic biologic therapies — directly comparable to Pure Infusion's home infusion service line.
• Option Care Health: Largest independent provider of home and alternate-site infusion services in the U.S., offering specialty infusion, home infusion, and chronic-disease biologic therapies comparable to Pure Infusion's suite of services.
• BioPlus Specialty Pharmacy: Specialty infusion pharmacy providing biologic therapies for chronic conditions including autoimmune, oncology, and neurology — overlaps directly with Pure Infusion's 87-therapy chronic-condition portfolio.

Broad incumbents

• Optum Infusion (UnitedHealth Group): National infusion and specialty pharmacy services arm of UnitedHealth Group/Optum, competing with Pure Infusion via Optum's vertically integrated payer-provider relationships.
• Coram (CVS Health Infusion Services): National home and outpatient infusion services arm of CVS Health, offering competing infusion therapy and specialty pharmacy capabilities with the backing of a vertically integrated payer/PBM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/aleracare

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AleraCare Holdings